Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Levodopa administration and multiple primary cutaneous melanomas

J E Bernstein, M Medenica, K Soltani

    Archives of Dermatology
    |September 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Studies on the parenteral administration of hydrogen peroxide.

    Federation proceedings·2010
    Same author

    Update on cicatricial alopecia.

    The journal of investigative dermatology. Symposium proceedings·2003
    Same author

    Pathology of AA amyloidosis in domestic sheep and goats.

    Veterinary pathology·2003
    Same author

    Amniotic membrane transplantation for reconstruction after excision of large ocular surface neoplasias.

    The British journal of ophthalmology·2002
    Same author

    Advances in ocular allergy: basic mechanisms, clinical patterns and new therapies.

    Current opinion in allergy and clinical immunology·2002
    Same author

    Regulation of MMP-9 production by human corneal epithelial cells.

    Experimental eye research·2002

    Levodopa, used for Parkinson's disease, may be linked to melanoma development. Long-term use in a patient correlated with three primary melanomas, suggesting cautious monitoring of skin changes.

    Area of Science:

    • Oncology
    • Dermatology
    • Pharmacology

    Background:

    • Malignant melanoma originates from melanocytes, cells with a unique pathway for converting levodopa to melanin.
    • Levodopa is a key medication for Parkinson's disease.
    • Previous observations suggest a potential link between levodopa therapy and melanoma incidence.

    Observation:

    • A 74-year-old woman developed three distinct primary melanomas.
    • The patient had a history of long-term treatment with levodopa and a decarboxylase inhibitor.
    • Histological examination confirmed these lesions as primary melanomas, distinct from metastatic melanoma.

    Findings:

    • The case report details the development of multiple primary melanomas in a patient undergoing long-term levodopa therapy.

    Related Experiment Videos

  • The observed melanomas were histologically differentiated from epidermotropic metastatic melanoma.
  • While the association remains tentative, the findings warrant attention.

    • Implications:

    • The study advises careful monitoring for pigmentary changes in patients receiving levodopa.
    • This highlights a potential, though tenuous, association between levodopa and melanoma risk.
    • Further research may be needed to clarify the relationship between levodopa and melanoma development.